Latest News

Trump administration's contradictory drug pricing policies undermine goals of affordability and innovation incentives.

Federal spending cuts disproportionately impact vulnerable populations relying on safety-net programs and community health services.

State Prescription Drug Affordability Boards limit public input while basing pricing decisions on flawed methodologies.

Copay accumulator programs exclude patient assistance from deductibles, creating barriers to medication adherence and treatment.

Proposed Medicaid cuts and work requirements threaten coverage for millions including people living with HIV.

FTC investigation confirms pharmacy benefit managers extracted billions in excess revenue through specialty drug markup schemes.

Insurance companies deploy AI algorithms for automated prior authorization denials, restricting patient access to prescribed treatments.

Pragmatic approach to healthcare policy reform requires accepting incremental progress while maintaining advocacy commitment.

Pugh reflects on 340B policy and patient advocacy in ensuring equitable medication access.

Proposed Cigna-Humana merger implications for healthcare competition and access.

Federal policy failures on copay accumulator programs restrict patient assistance benefits.

FTC complaint against major PBMs for anticompetitive rebating and insulin pricing.

ADA conflicts with state prescription drug affordability board operations.

FTC enforcement against hospital mergers and implications for costs and access.

Potential harms of state PDABs on HIV treatment access and ending the epidemic.

Unintended consequences of Inflation Reduction Act drug pricing provisions.

Copay accumulator schemes and Essential Health Benefits loophole; Louisiana as model.

How payor cost-containment strategies drive health disparities and limit care access.

PBM practices and supply chain vulnerabilities enable counterfeit drug distribution.

State-level PDAB implementation advancing despite patient advocacy concerns.